Abivax S.A.
ABVX
Classement en actions
#2353
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Prix de l'action
$94.73
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$8.27B
Changement (1 jour)
-4.07%
Changement (1 an)
7.19%
Pays
FR
Échange Abivax S.A. (ABVX)
Catégorie
Healthcare
Nombre d'actions en circulation pour Abivax S.A. (ABVX)
Nombre d'actions en circulation au October 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Abivax S.A., le nombre actuel d'actions en circulation est de 0. À la fin de October 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Abivax S.A. (ABVX) de 2013 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2025 | 69.53M | 10.28% |
| 2024 | 63.05M | 46.39% |
| 2023 | 43.07M | 125.57% |
| 2022 | 19.09M | 23.53% |
| 2021 | 15.46M | 8.03% |
| 2020 | 14.31M | 17.45% |
| 2019 | 12.18M | 19.71% |
| 2018 | 10.18M | 3.09% |
| 2017 | 9.87M | 2.26% |
| 2016 | 9.65M | -0.01% |
| 2015 | 9.65M | 39.61% |
| 2014 | 6.91M | -25.43% |
| 2013 | 9.27M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| - | - |
CH
|
